PYRGF vs. AVIR, KMDA, ME, RVNC, CRMD, XOMA, MRSN, VNDA, XERS, and ANL
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Atea Pharmaceuticals (AVIR), Kamada (KMDA), 23andMe (ME), Revance Therapeutics (RVNC), CorMedix (CRMD), XOMA (XOMA), Mersana Therapeutics (MRSN), Vanda Pharmaceuticals (VNDA), Xeris Biopharma (XERS), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical preparations" industry.
Atea Pharmaceuticals (NASDAQ:AVIR) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
Atea Pharmaceuticals has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 17.8% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, PyroGenesis Canada had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for PyroGenesis Canada and 2 mentions for Atea Pharmaceuticals. PyroGenesis Canada's average media sentiment score of 0.94 beat Atea Pharmaceuticals' score of 0.53 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.
Atea Pharmaceuticals received 17 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
PyroGenesis Canada has lower revenue, but higher earnings than Atea Pharmaceuticals. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Atea Pharmaceuticals has a net margin of 0.00% compared to Atea Pharmaceuticals' net margin of -201.83%. PyroGenesis Canada's return on equity of -29.18% beat Atea Pharmaceuticals' return on equity.
Summary
Atea Pharmaceuticals beats PyroGenesis Canada on 8 of the 14 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
